The Effects of Aspirin in Gestation and Reproduction

Completed · Not applicable · Has a placebo group

Conditions studied: Birth, Spontaneous Abortion

In brief

The primary objective of the study is to help elucidate the effects of low-dose aspirin in combination with folic acid on the incidence of live births and spontaneous abortions among a group of women who become pregnant compared to a control group.

Key facts

Study ID

NCT00467363

Run by

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

People needed

1228

Starts

2007-06-01

Expected to finish

2012-07-01

Last updated by the study team

2017-02-03

Who can join

Age: 18 and older, up to 40. Sex: female. Healthy volunteers: accepted.

You may qualify if…

• Women experiencing one or two pregnancy losses at any point in gestation in the past that were not elective termination(s). At least one of these losses must be well documented by one of the following:
• Sonogram demonstrating anembryonic loss, embryonic loss or fetal death.
• Histologic confirmation of products of conception that were spontaneously passed per vagina or surgically obtained.
• Hospital records of fetus delivery.
• Late menses and positive serum hCG or positive urine hCG documented by hospital or clinic records followed by either a negative hospital/clinic pregnancy test or a decline in urinary hCG level over 3 days.
• Home pregnancy tests without hCG confirmation from a healthcare provider (either serum or urine) will not be accepted.
• No more than 5 pregnancies in total including the pregnancy loss(es).*
• Up to two prior pregnancies that did not end in a loss.*
• Women may have up to two pregnancies beyond 20 weeks that were not losses, two spontaneous pregnancy losses at any time in the past, and up to one therapeutic or elective termination (two therapeutic or elective terminations if no other pregnancies). Ectopic and molar pregnancies would, for the purpose of enrollment, be considered in the same category as therapeutic termination pregnancies. Women with more than two live births or those with more than two losses, regardless of the week of gestation of the loss, are excluded.
• Presence of intact tubes (both), ovaries (both), and uterus.
• Between 18 and 40 years of age at time of baseline visit.
• Regular menstrual periods between 21 - 42 days in length (within the last 12 months). Regular menstrual periods are defined as no more than an 8-day difference between the woman's shortest and longest cycle.
• No more than one missed menses in the past 12 months (other than those missed due to pregnancy or breastfeeding).
• Actively trying to conceive with a male partner and not using contraception by the baseline visit.
• Not currently pregnant at the baseline or randomization visits.
• Ability and willingness to give informed consent.
• Willingness to be randomized and to take daily study pills for 6 months to a possible 15 months
• Exclusions Criteria:
• Known allergies to aspirin or non-steroidal anti-inflammatory agents.
• Clinical indication for anticoagulant therapy. These include prior or current thrombosis, antiphospholipid syndrome (APS) or known major thrombophilia.
• Clinical indication for chronic use of NSAIDs such as rheumatoid arthritis.
• Indication for additional folic acid supplementation, such as prior infant with neural tube defect (NTD), seizure disorder.
• Medical contraindication to aspirin therapy. These include uncontrolled asthma, nasal polyps, bleeding disorders, or history of gastrointestinal ulcer.
• Presence of major medical disorders (regardless of severity). These include diabetes, hypertension, systemic lupus erythematosus (SLE), untreated or active cancer (any cancer in remission or non-melanoma skin cancer is not included in the exclusion criteria), liver disease, renal disease, rheumatoid arthritis, cardiac disease, pulmonary disease other than mild asthma, neurologic disease requiring medical treatment, uncontrolled hypothyroidism, uncontrolled seizure disorder. Untreated vitamin B12 deficiency, severe anemia (Hct < 30%), hemophilia, gout, nasal polyps, among others.
• Currently undergoing/planned use of assisted reproductive techniques during trial (IVF; IUI; Clomid).

Where it is running

• University of Colorado, Denver School of Medicine, Department of Obstetrics and Gynecology — Denver, Colorado, United States
• Women's Health Research Center, Department of Social and Preventive Medicine, University at Buffalo — Buffalo, New York, United States
• Moses Taylor Hospital — Scranton, Pennsylvania, United States
• University of Utah Medical Center — Salt Lake City, Utah, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.